Imunomodulators in the treatment of malignant melanoma

Imunomodulatorji pri zdravljenju malignega melanoma

a case report

Authors

  • Tanja Mesti Onkološki inštitut, Ljubljana
  • Marko Boc Onkološki inštitut, Ljubljana
  • Martina Reberšek Onkološki inštitut, Ljubljana

Keywords:

immunomodulators, melanomas, malignant melanomas, treatment

Abstract

The incidence of melanoma is increasing, both in Slovenia and world-wide, more than any other form of cancer. According to the Cancer Registry of Slovenia, 415 patients were diagnosed with this disease in 2009 (1). Surgical removal of skin melanoma is the primary curative treatment for patients with early-stage disease. There are approximately 80% of such patients. In high-risk patients (around 10%), we also recommend treatment with high doses of interferon-α2b (2, 3). Metastatic melanoma is still an incurable disease with a 5-year survival of less than 5%. However, the prognosis for these patients has improved in the last few years, thanks to new developments in the field of systemic treatment. Besides standard treatment with systemic chemotherapy, new registered medicines are now also available with a different mechanism of action than chemotherapy, such as immunotherapy with the monoclonal antibody ipilimumab, BRAF inhibitors vemurafenib and dabrafenib, and MEK inhibitors (2, 3).

Povzetek

Ni abstrakta.

Downloads

Published

2013-12-15

Issue

Vol. 17 No. 2 (2013)

Section

Review Article

License

The journal is published under the terms of the Creative Commons Attribution License CC-BY 4.0. The authors retain the copyright to their work without any restrictions whatsoever.

This journal is an open-access journal, meaning that all of its contents are freely accessible without any charge to the user or their institution. In accordance with the Budapest Open Access Initiative (BOAI) definition of open access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking for prior permission from the publisher or the author, provided the authors and the journal are appropriately credited.

How to Cite

Imunomodulators in the treatment of malignant melanoma: a case report. (2013). Onkologija, 17(2), 139-142. https://revijaonkologija.si/Onkologija/article/view/190